CRANBURY, N.J. A former Wyeth executive will join the board of a company biotech company that develops vaccines.
VaxInnate announced Wednesday the appointment of Thomas Hofstaetter as COO. Hofstaetter was previously SVP corporate business development at Wyeth, from 2004 until the company’s recent acquisition by Pfizer. He has worked in leadership positions for the pharmaceutical industry for more than 30 years in the United States, Japan, France and his native Germany.
“We are delighted that Thomas Hofstaetter is bringing his business and scientific acumen to the VaxInnate team and look forward to tapping his experience to make VaxInnate a key player in the vaccine field,” VaxInnate president and CEO Alan Shaw said.